Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 1/2 2Phase NA 1Phase 2/3 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Hepatocellular 28Carcinoma, Non-Small-Cell Lung 27Colorectal Neoplasms 17Esophageal Squamous Cell Carcinoma 14Stomach Neoplasms 13Squamous Cell Carcinoma of Head and Neck 13Esophageal Neoplasms 12Cholangiocarcinoma 10Lung Neoplasms 9Head and Neck Neoplasms 9Uterine Cervical Neoplasms 8Small Cell Lung Carcinoma 8Triple Negative Breast Neoplasms 7Rectal Neoplasms 7Nasopharyngeal Carcinoma 6Melanoma 5Colonic Neoplasms 5Recurrence 4Pancreatic Neoplasms 4Locally Advanced Rectal Cancer 4Hodgkin Disease 4Neoplasms 3NSCLC 3Lymphoma, Extranodal NK-T-Cell 3Glioblastoma 3Carcinoma, Transitional Cell 3Biliary Tract Neoplasms 3Adenocarcinoma 3Urinary Bladder Neoplasms 2Thyroid Neoplasms 2

Interventions

toripalimab 2Injections 2ulixertinib 1tislelizumab 1spartalizumab 1lenvatinib 1famitinib 1erdafitinib 1camrelizumab 1Oxaliplatin 1Leucovorin 1Irinotecan 1Gemcitabine 1Docetaxel 1Cisplatin 1Capecitabine 15-fluorouridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Advanced Solid Tumor × tislelizumab × Clear all
NCT05014828 2025-08-24

To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors

BeiGene

Phase 2 Completed
58 enrolled 16 charts
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡